Spark, Novartis’s inherited blindness therapy Luxturna wins approval in Europe

Spark, Novartis’s inherited blindness therapy Luxturna wins approval in Europe

The company expects reimbursement decisions by national-level authorities in 2019 and 2020. The UK’s NICE recommended Cancer Drugs Fund coverage for another high-priced Novartis therapy, the CAR-T Kymriah, earlier this month.

Source: https://ift.tt/2zCLRSf